Corpus ID: 30510288

[Comparative clinical trial of vaccines against avian influenza].

  title={[Comparative clinical trial of vaccines against avian influenza].},
  author={V. Zverev and A. V. Katlinskii and M. P. Kostinov and S. N. Zhirova and M. Erofeeva and M. Stukova and S. Korovkin and S. I. Mel'nikov and A. Semchenko and A. Mironov},
  journal={Zhurnal mikrobiologii, epidemiologii, i immunobiologii},
Scientic-production association "Microgen" has finished 1st phase of clinical trials of candidate vaccines against avian influenza in order to assess their reactogenicity, safety, and immunogenicity. Two vaccines constructed from NIBRG-14 vaccine strain [A/Vietnam/1 194/2004 (H5N1)], obtained from World Health Organization, were studied: "OrniFlu" (inactivated subunit influenza vaccine adsorbed on aluminium hydroxide) and inactivated polymer-subunit influenza vaccine with polyoxydonium (IPSIV… Expand

Topics from this paper

Immunogenicity and adverse events of avian influenza A H5N1 vaccine in healthy adults: multiple-treatments meta-analysis.
Currently, H5N1 influenza vaccines with non-aluminium adjuvants might represent the best available option in a pandemic, but large-scale studies are needed to verify the high immunogenicity of non- aluminium-adjuvanted vaccines that use very low doses of antigen. Expand
Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine
It was found that priming with A(H5N2) LAIV induced a long-lasting B-cell immunological memory against influenza A( H5N1) virus, which was brought on by more prompt and vigorous antibody production to a single dose of A (H5 N1) IIV in the primed group, compared to the naïve controls. Expand
Effectiveness and Cost-Effectiveness of Expanded Antiviral Prophylaxis and Adjuvanted Vaccination Strategies for an Influenza A (H5N1) Pandemic
This decision model for pandemic planning suggests that stockpiling sufficient adjuvanted vaccine for immunizing 40% of the population is more effective and cost-effective than immunizing a smaller proportion of the Population or providing them with antiviral drugs. Expand
Pre-pandemic and pandemic influenza vaccines
This review explores developing pandemic and pre-pandemic vaccines in the context of highly virulent avian H5N1 virus and the influenza H1N1 pandemic of 2009. Expand
Effectiveness and Cost-Effectiveness of Expanded Antiviral Prophylaxis and Adjuvanted Vaccination Strategies for an Influenza A ( H 5 N 1 ) Pandemic
Interventions: 3 scenarios: 1) vaccination and antiviral pharmacotherapy in quantities similar to those currently available in the U.S. stockpile (stockpiled strategy), 2) stockpiled strategy butExpand
The pivotal roles of the host immune response in the fine-tuning the infection and the development of the vaccines for SARS-CoV-2
The potential roles of host immune response in the modulation of the outcomes of SARS-CoV infections and the current progress of some already deployed vaccines worldwide as well as those still in the pipelines are highlighted. Expand
Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic.
Proper planning for an influenza A (H5N1) pandemic is a public health priority and a strategy with vaccination and extended vaccination is recommended. Expand